Krystal Biotech (KRYS) Convertible Debt (2016)

Krystal Biotech (KRYS) reported Convertible Debt of $1.1 million for Q4 2016.

Krystal Biotech (KRYS) Convertible Debt (2016) Analysis & Trends

Krystal Biotech (KRYS) has 1 years of Convertible Debt data on file, last reported at $1.1 million in Q4 2016.

For the quarter ending Q4 2016, Convertible Debt changed N/A year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2016 stood at $1.1 million (changed N/A YoY), and the FY2016 full-year result was $1.1 million, changed N/A from the prior year.
Convertible Debt was little changed at $1.1 million in Q4 2016.
In the past five years, Convertible Debt ranged from a high of $1.1 million in Q4 2016 to a low of $1.1 million in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Krystal Biotech	9.59 Bn	8.77 Bn	110.08 Mn

Download Data

Date	Value
Dec 31, 2016	1.15 Mn